AI Terminal
Ananda Pharma Plc
Pre-Annual General Meeting Information • Jul 30, 2025
10286_rns_2025-07-30_80803848-b4f0-4c6a-a7e0-6b5b4dff8faf.html
Pre-Annual General Meeting Information
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information 
RNS Number : 2396T
Ananda Pharma PLC
30 July 2025
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU, WHICH IS PART OF UNITED KINGDOM DOMESTIC LAW PURSUANT TO THE MARKET ABUSE (AMENDMENT) (EU EXIT) REGULATIONS (SI 2019/310) ("UK MAR"). UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION (AS DEFINED IN UK MAR) IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.
30 July 202 5
ANANDA PHARMA PLC
("Ananda" or the "Company")
Notice of Annual General Meeting
Ananda Pharma plc (AQSE: ANA, OTCQB: ANANF), a UK-based biopharmaceutical company developing regulatory approved, cannabidiol medicines to treat complex, chronic conditions, is pleased to announce that notice convening the Company's Annual General Meeting ("AGM") for 2.00pm BST on 26 August 2025 at the offices of Arch Law, Level 2, Huckletree, 8 Bishopsgate, London, EC2N 4BQ, has been sent to shareholders of the Company.
Full details of the resolutions proposed to the shareholders are available within the Notice of Meeting, available at https://investors.anandapharma.co.uk/s/0e221d under the Notices and Meetings tab.
Melissa Sturgess will be giving a corporate update presentation and Q&A session via the Company's InvestorHub on 12th of August 2025 at 12.00pm.
The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via the webinar page up until 12.00pm on 11th of August 2025, or at anytime during the live presentation.
Investors can sign up to the webinar for free via: https://investors.anandapharma.co.uk/s/09bdfb .
About Ananda Pharma
Ananda Pharma (AQSE: ANA) is a UK-based biopharmaceutical company developing regulatory approved , cannabidiol medicines to treat complex, chronic conditions, including epilepsy (trials funded by NHS England and NIHR), endometriosis (funded by NHS Scotland) and chemotherapy pain (funded by NIHR). The Company is led by successful entrepreneurs and is working with a team of world-class scientists, including globally respected Key Opinion Leaders at the University of Edinburgh, Great Ormond Street Hospital for Children and University College London.
For more information, please visit our website :
To stay up to date with Ananda's news please follow our social media channels:
· Investor Hub: https://investors.anandapharma.co.uk/s/ea8f93
· Instagram: https://www.instagram.com/anandapharmaplc/
· LinkedIn : https://www.linkedin.com/company/anandapharma
· X : https://twitter.com/AnandaPlc
· Investor Meet Company: https://www.investormeetcompany.com/ananda-pharma-plc/register-investor
-Ends-
For the purposes of UK MAR, the Directors of the Company accept responsibility for the contents of this announcement.
| ANANDA PHARMA PLC | +44 (0)7463 686 497 |
| [email protected] | |
| Chief Executive Officer | |
| Melissa Sturgess | |
| Finance Director | |
| Jeremy Sturgess-Smith | |
| SP ANGEL CORPORATE FINANCE LLP | |
| Corporate Broking | +44 (0)20 3470 0534 |
| Abigail Wayne | [email protected] |
| Rob Rees | [email protected] |
| Corporate Finance | +44 (0)20 3470 0470 |
| Richard Morrison | |
| Josh Ray | |
| VIRIDIAN CAPITAL ADVISORS (US) Scott Greiper |
+1 (646) 330-0704 [email protected] |
| YELLOW JERSEY PR Sarah MacLeod Charles Goodwin Zara McKinlay |
+44 (0)20 3004 9512 [email protected] |
https://investors.anandapharma.co.uk/link/y05zke
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
NEXRMMTTMTIJBRA